Myomo and Elevance Health Agree to Contract for Multi-State Network Participation
MWN-AI** Summary
Myomo, Inc. (NYSE American: MYO), specializing in wearable medical robotics, has announced a partnership with Elevance Health to create network participation agreements across multiple states. This strategic collaboration is expected to enhance access to Myomo's MyoPro® powered arm and hand orthoses, particularly for individuals suffering from neurological disorders and upper-limb paralysis. The agreements, covering Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans, will roll out market by market through the second quarter of 2026. By the completion of this process, Myomo anticipates that it will expand its reach to over 80 million lives under commercial insurance.
Dr. Harry Kovelman, Myomo's Chief Medical Officer, expressed enthusiasm about this partnership, emphasizing the shared goal of improving patients' function and independence through innovative technologies that are cost-effective. MyoPro, the company’s flagship product, is designed to assist those facing challenges such as stroke, brachial plexus injury, and other neuromuscular conditions, allowing patients to regain capabilities that support daily activities and foster independence.
Elevance Health serves approximately 115 million consumers, offering extensive healthcare solutions. Through this partnership, Myomo aims to further its mission of enabling individuals to perform everyday tasks, thus reducing overall care costs while enhancing quality of life.
Both companies acknowledge the importance of navigating various challenges ahead, including securing sufficient reimbursement from payers and managing business scalability. The collaborative effort marks a significant step towards broader access to Myomo’s unique solutions and highlights the commitment of both Myomo and Elevance Health to improve health outcomes for their members.
MWN-AI** Analysis
The recent contract between Myomo, Inc. (NYSE American: MYO) and Elevance Health represents a significant strategic move for both companies that can impact investor sentiment and financial performance in the coming years. Myomo’s innovative MyoPro® powered arm and hand orthoses cater to a niche yet critical market—individuals suffering from neurological disorders and upper-limb paralysis. With Elevance Health providing access to a vast network of 45 million medical members, Myomo anticipates that its covered lives will exceed 80 million, substantially broadening its potential customer base.
Investors should take this opportunity to assess Myomo's revenue growth potential. The deal not only enhances visibility for the MyoPro product line but it also positions Myomo to capture a larger share of the healthcare spending directed towards rehabilitation technologies. The ability to offer these orthoses under commercial and government insurance plans improves affordability for users, which could lead to increased adoption rates and ultimately higher revenue streams for Myomo.
However, investors must exercise caution. The success of these agreements hinges on several factors, including Myomo’s ability to navigate reimbursement processes effectively. Additionally, potential supply chain disruptions and competition in the adaptive technology space may pose challenges to operational scaling. Investors should closely monitor Myomo’s performance in achieving strategic milestones outlined in their forward-looking statements.
In conclusion, the partnership with Elevance Health is a promising development for Myomo, presenting a dual opportunity for market expansion and increased patient accessibility. While the upside is significant, the inherent risks in this evolving sector warrant a cautious approach. Investors might consider an incremental position in Myomo stock, while keeping a watchful eye on execution and market dynamics over the next few quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo’s total number of covered lives under commercial insurance plans to over 80 million.
These agreements are expected to expand access to Myomo’s MyoPro® powered arm and hand orthoses, while supporting affordability for plan members and their families on an in-network basis.
“We are pleased to partner with Elevance Health’s affiliated plans to bring the benefits of MyoPro to their members,” said Dr. Harry Kovelman, Myomo’s Chief Medical Officer. “This arrangement with Elevance reinforces our commitment to helping individuals regain function and independence through clinically proven, innovative technologies delivered in a cost-effective manner.”
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve roughly 115 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information please visit www.myomo.com .
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations regarding the effective dates of state contracts and expansion of access to the MyoPro, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.
These factors include, among other things:
- our ability to obtain sufficient reimbursement from third-party payers for our products;
- our dependence on external sources for the financing of our operations;
- our ability to scale the business to achieve positive cash flow from operations;
- our revenue concentration with patients who carry Medicare Part B;
- our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
- our marketing and commercialization efforts;
- our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
- our expectations as to our product development programs, including improving our existing products and developing new products;
- our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
- our expectations as to our clinical research program and clinical results;
- our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
- our ability to gain and maintain regulatory approvals;
- our ability to compete and succeed in a highly competitive and evolving industry; and
- general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.
More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260309846420/en/
Myomo:
ir@myomo.com
Alliance Advisors IR:
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
FAQ**
How will the network participation agreements with Elevance Health impact Myomo Inc. (MYO)'s financial performance and market reach over the next few years?
What strategies does Myomo Inc. (MYO) plan to implement to ensure the successful scaling of its operations and maintain positive cash flow?
Can you elaborate on the expected clinical outcomes and user feedback for Myomo Inc. (MYO)'s MyoPro devices following the expansion of access through Elevance Health's plans?
What measures is Myomo Inc. (MYO) taking to navigate potential risks related to reimbursement, supply chain, and regulatory approvals as it grows its market presence?
**MWN-AI FAQ is based on asking OpenAI questions about Myomo Inc. (NYSE: MYO).
NASDAQ: MYO
MYO Trading
1.85% G/L:
$0.7204 Last:
154,628 Volume:
$0.7172 Open:
